An open-label trial found that pioglitazone/metformin plus dapagliflozin did not beat basal insulin/metformin on its primary glycaemic endpoint, with secondary metabolic signals favouring the oral regimen. PICO summary and expert commentary.
Browsing: Diabetes & Glycaemic Control
Diabetes and glycaemic-control evidence summaries covering HbA1c, glucose monitoring, medication comparisons, hypoglycaemia, patient-reported outcomes, and clinical interpretation.
A post hoc analysis of SUSTAIN China examining whether the glycaemic efficacy of once-weekly semaglutide versus sitagliptin in adults with type 2 diabetes varies by baseline characteristics. PICO summary and expert commentary.
A manufacturer-sponsored 28-week RCT used mixed-meal testing to compare how tirzepatide and semaglutide improve glucose control in type 2 diabetes. PICO summary and expert commentary.
PIONEER 12 was a 26-week double-blind Phase IIIa trial showing all three doses of once-daily oral semaglutide lowered HbA1c and body weight more than sitagliptin 100 mg in a predominantly Chinese type 2 diabetes population. PICO summary and expert commentary.
Phase IIIa double-blind trial of oral semaglutide monotherapy vs placebo in a predominantly Chinese type 2 diabetes population, with HbA1c and body-weight findings. PICO summary and expert commentary.
PIONEER 12 was a 26-week, double-blind, manufacturer-sponsored Phase IIIa trial showing oral semaglutide lowered HbA1c and body weight more than sitagliptin in a predominantly Chinese population with type 2 diabetes. PICO summary and expert commentary.
A post hoc analysis of the SURPASS program found tirzepatide produced similar HbA1c, weight, and cardiometabolic improvements whether type 2 diabetes was diagnosed before or after age 40. PICO summary and expert commentary.
A single-center randomized controlled trial testing a cloud-hospital data platform plus dietary management against standard care in 180 adults with type 2 diabetes, reporting a modest 12-week HbA1c advantage. PICO summary and expert commentary.
A post hoc analysis of the SUSTAIN China trial found that the glycaemic efficacy of once-weekly semaglutide versus sitagliptin was consistent across most baseline subgroups. PICO summary and expert commentary.
A model-based analysis of a 28-week randomized meal-test substudy comparing tirzepatide 15 mg with semaglutide 1 mg in metformin-treated type 2 diabetes. PICO summary and expert commentary.